Develops antibody therapeutics using its Probody platform to treat cancer and other serious diseases.
CytomX Therapeutics, Inc. is a leading oncology-focused biopharmaceutical company based in South San Francisco, California, dedicated to pioneering antibody therapeutics using its innovative Probody technology platform. This platform enhances cancer treatment by targeting therapies more precisely within the body.
The company's robust pipeline includes several promising product candidates at various stages of clinical development. Among these are CX-2009, an antibody drug conjugate targeting CD166, currently in Phase II clinical trials for breast cancer treatment; and CX-2029, also in Phase II trials, addressing squamous non-small cell lung cancer, head and neck squamous cell carcinoma, and other cancers. Additionally, CytomX is advancing BMS-986249 and BMS-986288, both CTLA-4 Probody therapeutics, through Phase I and Phase I/II trials respectively, targeting metastatic melanoma and solid tumors.
Innovative initiatives continue with CX-2043, a conditionally activated antibody drug conjugate aimed at the epithelial cell adhesion molecule, and CX-904, designed for epidermal growth factor receptor treatment in solid tumors. CytomX Therapeutics collaborates strategically with industry leaders such as AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas Pharma to advance Probody therapeutics and broaden treatment options for cancer patients worldwide. Founded in 2008, the company remains committed to pioneering advancements in oncology therapy through rigorous research and strategic partnerships.